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Abstract: We report a method, Expression-Microarray Copy Number Analysis (ECNA) for the detection of copy number 
changes using Affymetrix Human Genome U133 Plus 2.0 arrays, starting with as little as 5 ng input genomic DNA. An 
analytical approach was developed using DNA isolated from cell lines containing various X-chromosome numbers, and 
validated with DNA from cell lines with deﬁ  ned deletions and ampliﬁ  cations in other chromosomal locations. We applied 
this method to examine the copy number changes in DNA from 5 frozen gastrointestinal stromal tumors (GIST). We detected 
known copy number aberrations consistent with previously published results using conventional or BAC-array CGH, as 
well as novel changes in GIST tumors. These changes were concordant with results from Affymetrix 100K human SNP 
mapping arrays. Gene expression data for these GIST samples had previously been generated on U133A arrays, allowing 
us to explore correlations between chromosomal copy number and RNA expression levels. One of the novel aberrations 
identiﬁ  ed in the GIST samples, a previously unreported gain on 1q21.1 containing the PEX11B gene, was conﬁ  rmed in this 
study by FISH and was also shown to have signiﬁ  cant differences in expression pattern when compared to a control sample. 
In summary, we have demonstrated the use of gene expression microarrays for the detection of genomic copy number aber-
rations in tumor samples. This method may be used to study copy number changes in other species for which RNA expres-
sion arrays are available, e.g. other mammals, plants, etc., and for which SNPs have not yet been mapped.
Keywords: copy number change, gene expression, array-based comparative genomic hybridization, whole genome 
ampliﬁ  cation, GIST, sarcoma
Introduction
Chromosomal aberrations are frequently observed in cancer, and whole-genome analysis of copy number 
change in tumor cells has become a useful tool for tumor classiﬁ  cation, tumor marker discovery, and 
for studying tumorigenesis. The initial application of chromosomal comparative genomic hybridization 
(CGH), co-hybridizing differentially labeled tumor and normal genomic DNA to normal metaphase 
spreads, identiﬁ  ed genomic regions of deletions and ampliﬁ  cations in various tumor samples and cell 
lines (1), allowing copy number estimation at around 10 megabase resolution. Recent advances in 
microarray technology have provided higher resolution tools for genome wide analysis of copy number 
estimations. An early array-based study used a spotted chromosome-speciﬁ  c library or cloned genomic 
fragments to investigate copy number changes in tumor samples (2). Later developments, using micro-
arrays derived from genomic clones (3), cDNA (4), BAC clones (5) and oligonucleotides (6–12) provided 
higher resolution analyses. By using high-density SNP oligonucleotide microarrays, Bignell et al. (8) 
described an assay and algorithm for copy number analysis on various cancer cell lines to identify 
homozygous deletions and high-level ampliﬁ  cation. Other oligonucleotide-based microarray studies 
used longer oligos, 60- or 70-mers, to identify copy number changes in cancer cells (6, 7).
Gene expression profiles have been used successfully to classify tumors (13), (14), including 
gastrointestinal stromal tumors (15). To better understand the role of DNA copy number aberration in 
tumorigenesis, efforts have been made to correlate gene expression patterns to speciﬁ  c genomic alterations 
(16–22). While genes in the altered genomic regions are not necessarily regulated by DNA dosage, copy 
number aberrations may inﬂ  uence genome-wide gene expression patterns. If both genomic DNA and RNA 
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are available from the same sample, both copy num-
ber analysis and RNA expression analysis can be 
performed on the same arrays. Thus, it is possible to 
assess whether a probeset is in a region that is both 
ampliﬁ  ed and over-expressed. Such regions may be 
of greater interest for further study, both to under-
stand the pathogenesis of disease and to explore the 
possibility of discovering diagnostic biomarkers.
Gastrointestinal stromal tumor (GIST) is the 
most common mesenchymal tumor of the intestinal 
tract (23). GISTs express KIT protein and show 
in a significant number of cases activating 
mutations in either KIT or PDGFRA genes, 
encoding for class III tyrosine kinase receptors 
(24, 25). Cytogenetically, GISTs show a rather 
simple karyotype with common losses of 
chromosome 14, 22 and 1p, in most cases, 
regardless of the KIT genotype. Since these simple 
genomic copy number aberrations have been 
previously conﬁ  rmed by metaphase CGH (26–28) 
and BAC-array analysis (29), GIST represents an 
ideal tumor model for evaluating array-based 
methods for copy number analysis.
In this study, we describe an assay for detecting 
copy number changes by hybridizing genomic DNA 
to oligonucleotide microarrays designed for RNA 
expression proﬁ  ling. We applied this approach to 
examine the genomic copy number changes among 
various cell lines and GIST tumors. Algorithm and 
method development were performed on cell lines 
containing various numbers of X chromosomes and 
known deletions and ampliﬁ  cations. This method, 
Expression-Microarray Copy Number Analysis 
(ECNA), allowed us to readily identify genes that 
showed copy number alterations starting with as 
little as 5 ng genomic DNA. ECNA was validated 
on GIST tumors in which previously described as 
well as novel copy number aberrations were 
identiﬁ  ed.
Materials and Methods
Cell lines and DNA
DNA samples used in this study fall into 3 catego-
ries: DNA extracted from cell lines, normal human 
blood, and GIST tumors. DNAs from cell lines 
containing different copy numbers for the X 
chromosome: 1X(NA01723A), 2X(NA09899), 
3X(NA04626), 4X(NA01416), and 5X(NA06061) 
chromosomes and from a Chromosome 4 deletion 
cell line (NA04126) were purchased from the 
National Institute of General Medical Sciences 
(NIGMS) Human Genetic Cell Repository, Coriell 
Institute for Medical Research (Camden, NJ). A 
human breast cancer cell line, SK-BR-3, was 
obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). DNA was extracted from 
the cultured cells using the DNA Maxi Kit (Qiagen, 
Inc., Valencia, CA). DNA from normal blood was 
obtained from AllCells, LLC (Emeryville, CA). 
GIST sample DNA was obtained using a standard 
organic phenol-chloroform procedure. There were 
5 GIST samples from 4 patients. Three of the 
samples were taken from the primary tumor resec-
tion, and in one patient two abdominal recurrences 
removed at different time points were analyzed 
(GIST#159, 199). The diagnosis was conﬁ  rmed by 
pathologic review and immunoreactivity for KIT. 
Three samples had a KIT exon 11 mutation (GIST# 
159, 198, 199) and 2 had a PDGFRA exon 18 dele-
tion (GIST#171, 204). All samples used for ECNA 
are listed in Supplementary Table 1.
Whole genome ampliﬁ  cations, puriﬁ  cation, 
fragmentation and labeling
5–25ng genomic DNA was ampliﬁ  ed using QIA-
GEN’s REPLI-g
® kit (Qiagen) for 16 hours at 
30 °C, according to the protocol provided by the 
Table 1
CGH methodology Gains Losses Reference
Conventional CGH 1p, 1q, 2q, 3q, 4, 5, 6p, 
7, 8, 9, 10, 11q, 12q, 16, 
17, 18, 19, 20
1p, 1q, 2, 3p, 4, 5p, 6q, 7p, 8p, 
9p, 9q, 10q, 11p, 12, 13q, 14, 
15q, 17p, 18q, 19q, 21, 22q
El-Rifai, 2000
BAC array CGH 3q 1p36, 6q12, 9p, 13q34, 14, 15, 
22
Granitto, 2004
ECNA* 1p, 1q, 2q, 3q, 4, 5, 6p, 
7, 8, 9, 10, 11q, 16, 17, 
18, 19
1p36, 1q, 3p, 9p, 9q, 10q, 11p, 
12, 13q34, 14q, 15q, 17p, 18q, 
19q, 21q22, 22q
Present study
*Seen in 2 GIST tumors; bolded regions indicate that were identiﬁ  ed by at least 2 CGH methods.
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manufacturer. Reaction volumes were between 150 
and 200 µL (2–5 µg/µL yield). DNA from GIST 
tumors has been previously used for reliable geno-
typing results. The ampliﬁ  cation products were 
purified by Qiagen genomic-tip (Qiagen) and 
quantiﬁ  ed using a NanoDrop
® spectrophotometer 
(NanoDrop Technologies, Wilmington, DE) at 260 
nm. Fragmentation of puriﬁ  ed DNA samples (100 
µg) was carried out by adding 0.2 Unit of DNAase 
I (DNA Fragmentation Reagent, Affymetrix, Inc.) 
in 1X of Fragmentation Buffer (Affymetrix, Inc.), 
then incubated at 37 °C for 30 min. The fragmen-
tation reaction was terminated by incubation at 
95 °C for 10 min. The fragmentation products were 
then terminally biotinylated with DNA Labeling 
Reagent (Affymetrix, Inc.) at 37 ºC for 5 hours. 
The labeled fragments were then concentrated on 
YM-3 Microcon columns (Millipore, Billerica, 
MA).
DNA hybridization, wash, staining 
and scanning
Labeled DNA fragments (0.5 µg/µl) were added 
in a hybridization mix containing: 1X HYB Mix, 
2.5X Denhardt’s Solution (Sigma, St. Louis, MO), 
0.125 µg/µl human Cot-1 DNA (Roche, Basel, 
Switzerland), 0.06 nM Oligo B2. (Affymetrix) and 
10% DMSO (Sigma). The hybridization mix was 
heated at 95 °C for 5 min, followed by immediate 
cooling, and then hybridized to the GeneChip
® 
Human Genome U133 Plus 2.0 arrays (Affymetrix) 
at 48 °C for 16 hours. After hybridization, arrays 
were washed with 3M TMACl in 0.4 × SSPE and 
0.01% Tween-20 solution for 30 min, then washed 
extensively with 0.1M NaCl in 0.6 × SSPE and 
0.01% Tween-20 prior to the staining. Arrays were 
ﬁ  rst stained with streptavidin, and then with a 
biotin-conjugated anti-streptavidin antibody, 
ﬁ  nally followed by staining with phycoerythrin—
streptavidin. Arrays were scanned using the 
Affymetrix GeneChip Scanner 3000 (Affymetrix). 
Image analysis was performed with GeneChip 
Software GCOS, version 1.2.
RNA hybridization to Affymetrix 
U133A arrays
RNA from 10 tumor samples (4 GISTs and 6 leio-
myosarcomas) was analyzed on Affymetrix human 
genome U133A arrays. Leiomyosarcomas, which 
are malignant mesenchymal neoplasms of smooth 
muscle derivation closely resembling GIST 
morphologically, but genetically distinct from 
GIST, were used as a control reference. RNA was 
isolated using the protocol accompanying the 
RNAwiz™ RNA Isolation Reagent from Ambion 
(Austin, TX) and all samples were treated on the 
column with RNase-free DNase (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions. 
Twenty-ﬁ  ve to 50 nanograms of total RNA were 
tested for quality on an RNA 6000 Nano Assay 
(Agilent, Palo Alto, CA) using a Bioanalyzer 2100. 
RNA with an OD260/280 ratio greater than 1.8 
was chosen for expression proﬁ  ling experiments. 
Two micrograms of high quality total RNA was 
then labeled according to protocols recommended 
by the manufacturer. Briefly, after reverse-
transcription with an oligo-dT-T7 (Genset), double 
stranded cDNA was generated with the Superscript 
double stranded cDNA synthesis custom kit (Invi-
trogen Life Technologies, Carlsbad, CA). In an in 
vitro transcription step with T7 RNA polymerase 
(MessageAmp™ RNA kit from Ambion) the 
cDNA was linearly ampliﬁ  ed and labeled with 
biotinylated nucleotides. Ten micrograms of 
labeled and fragmented cRNA were then hybrid-
ized onto a test array and a Human Genome U133A 
expression array (Affymetrix, containing probesets 
representing 18,000 transcripts and variants). Post 
hybridization staining and washing were processed 
according to the manufacturer (Affymetrix). 
Finally, chips were scanned with a GC3000 laser 
confocal scanner.
Data analysis of copy number change
The copy number analysis workﬂ  ow is summarized 
in Figure 1. The following steps were carried out 
sequentially: data normalization, data ﬁ  ltering, 
chromosome data mapping, reference and validation 
data set selection, DNA copy number estimation 
by computing a Z score and Stouffer Z score for 
each probe set, method validation and GIST 
samples copy number estimation. Details of the 
method are described in the Supplementary 
Materials and Methods.
Data analysis of RNA samples hybridized 
to U133A arrays
Analysis was performed using Affymetrix PLIER 
algorithm (Affymetrix Technical Note 1)(30). 
Principal Component Analysis (PCA) and one-
way ANOVA were performed using Partek 
software. Data visualization was rendered either 
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Figure 1. Copy number analysis workﬂ  ow. The steps for developing ECNA are shown here, along with the steps performed in parallel to 
analyze GIST copy number changes on the Mapping 100K SNP arrays and GIST RNA expression changes on U133A arrays. Details are 
in Supplement 2.
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by Partek
® Genomics Suite, version 6.2 or 
SpotFire
® DecisionSite™ version 8.1 software. 
One-way ANOVA analysis was used to compare 
the 4 GIST samples with a reference group of 6 
leiomyosarcoma tumors. Data mapping between 
RNA expression data and DNA copy number 
estimation was done by matching probe set names 
(U133 Plus 2.0 vs. U133A array) or by corre-
sponding chromosomal locations (U133 Plus 2.0 
vs. Mapping 100K array). Each step is described 
in detail in the Supplementary Materials and 
Methods.
100K human mapping arrays
For data validation, genomic DNA from the same 
4 GIST samples was hybridized on the 100K 
Human Mapping Arrays (31). The data was ana-
lyzed with Affymetrix GDAS software and the 
subsequent DNA copy number estimation was 
analyzed with Affymetrix DNA copy number tool 
CNAT (Affymetrix Technical Note 2) (32).
Fluorescence in situ hybridization (FISH)
FISH was performed in 3 GIST cases, using fresh 
frozen touch preparations from all 3 tumors, as well 
as on parafﬁ  n sections for 2 of these tumors. BAC 
clones for PRKAR2B and PEX11B were obtained 
from BACPAC Resources. The PRKAR2B probe 
comprised two overlapping BAC clones, RP11-
120N6 and RP11-258L19, labeled by nick 
translation with Spectrum Orange (Vysis, Abbott 
Laboratories, IL). A chromosome 7 centromeric 
plasmid probe (p7t1)(33) labeled with Spectrum 
Green (Vysis, Abbott Laboratories, IL) was used as 
reference. The PEX11B probe was a single BAC 
clone, RP11-315I20, labeled by nick translation 
with Spectrum Orange. The reference probe was a 
chromosome 1 centromeric plasmid probe 
(pSD1-1) (34) labeled with Spectrum Green. FISH 
was done according to standard procedures. Brieﬂ  y, 
touch preparations were ﬁ  xed in 3:1 methanol/ace-
tic acid and then pretreated with pepsin-HCl at 
37 ºC for 3 to 5 minutes, rinsed in PBS, ﬁ  xed in 1% 
formaldehyde, then rinsed, dehydrated, and air-
dried. Parafﬁ  n sections were de-waxed in xylenes, 
and then micro-waved in 10 mM sodium citrate 
(pH 6~6.5) solution for 5~10 minutes, cooled to 
room temperature, rinsed and dehydrated. The 
slides were then denatured in 70% formamide at 
68 ºC for 2 to 4 minutes. Approximately 100 ng of 
labeled BAC DNA and 2 µg Cot-1 DNA (Invitrogen), 
was ethanol-precipitated, and resuspended in 
hybridization buffer. The probe mix was then dena-
tured at 70 ºC for 10 minutes, followed by pre-
annealing at 37 ºC for 30 minutes. The reference 
probe was denatured separately, without pre-
annealing, and combined with the denatured 
reference probe on the slide for overnight incuba-
tion at 37 ºC. After standard post-hybridization 
washes, the slides were stained with 4’, 6-diamid-
ino-2-phenylindole (DAPI) and mounted in 
VECTASHIELD
® antifade mounting medium 
(Vector Laboratories). Analysis was done using a 
Nikon E800 epifluorescence microscope with 
MetaSystems Isis 3 imaging software. A minimum 
of 100 cells was scanned over separate regions for 
each slide. Image z-stacks were captured using a 
Zeiss Axioplan 2 motorized microscope controlled 
by Isis 5 software (Metasystems).
Results
Detection of copy number changes
To conﬁ  rm that differences in signal are propor-
tional to the differences in copy number, we per-
formed the assay on cell lines with variable 
numbers of X chromosomes ranging from 1 to 5 
copies. The probesets on the X chromosome show 
a proportional increase in signal (Fig. 2A) when 
each cell line is compared to a 1X cell line. The Z 
score, which provides a point estimation of copy 
number for each probeset, is derived by comparing 
the signal of each probeset in a sample to that of a 
reference sample set (Fig. 2B). Chromosomes other 
than the X chromosome were analyzed and found 
not to have copy number variation in the samples 
tested (data not shown).
In chromosomal copy number estimations, a 
range of values is typically seen. It is important 
to choose thresholds or cut-off values, above or 
below which a region may be called ampliﬁ  ed or 
deleted. The 69 samples that passed the 67% pres-
ent call rate cut-off value and used in these 
analyses (Supplementary Table 1), have known 
numbers of X chromosomes (Fig. 3). In this study, 
Z scores in windows of 500,000 bp were used to 
compute Stouffer Z values. The tighter distribu-
tion seen with the Stouffer Z sliding window 
approach reﬂ  ects the reduction of noise obtained 
(Figs. 3A, B) and was used for ﬁ  nal copy number 
estimations. A clear separation was observed 
between the median Stouffer Z scores for each of 




Figure 2. Detection of copy number changes in cell lines with variable numbers of X chromosomes. The X chromosome copy num-
ber of each sample is known, which is indicated on the x-axis. The box and whisker plot (35) represents the interquartile range (between 
25% and 75%) and the line within the box denotes the median. The whiskers extend to the last observation before the outliers, which are 
plotted individually as dots. Outliers of values greater than 7 are not plotted. A. The observed pair-wise signal ratio of each probe set on 
X-chromosome against a 1X sample is shown here. B. The Z-score, calculated using a reference set of 37 samples, shows similar results 
compared to the single sample reference in A.
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Figure 3. Correlation of signal with copy number. The box plots are derived from analyses performed on 69 samples, described in 
Materials and Methods, bearing 1 to 5 copies of the X chromosome. The lower and upper whiskers are at 10% and 90% respectively. A. Z 
score. B. Stouffer Z score. C. Stouffer Z score histograms. The distribution of Stouffer Z score for these samples is represented by the 
boxplots below the histograms. The median as indicated in the boxplots below the 5 distribution plots is then used to assess the copy num-
ber. D. The trimmed mean of Signal and the median values for each set of samples are shown here, along with the mean +/− 2 S.D.s. In 
this study, regions with Stouffer Z scores = 5.5, i.e. the mean Stouffer Z score for the 3X cell line + 2 S.D., are called as ampliﬁ  cations 




ChrXCopy Median Mean Std_Dev MeanMinus1SD MeanMinus2SD MeanPlus2SD MeanPlus1SD
1X -2.7 -3.1 2.3 -5.4 -7.7 1.6 -0.7
2X 0.1 0.0 1.8 -1.7 -3.5 3.6 1.8
3X 2.9 3.0 1.3 1.7 0.4 5.5 4.2
4X 4.8 5.0 2.1 2.9 0.7 9.3 7.2
5X 5.2 5.2 2.4 2.8 0.4 10.0 7.6
D
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the 5 sample sets, bearing 1 to 5 X-chromosome 
copies, and 2-fold changes could be distinguished 
by this method (Fig. 3C). In this model, a 2-fold 
change between 2X and 4X was easier to deter-
mine than the change between 1X and 2X. 
However, 3-fold or greater changes can be dis-
tinguished much more easily than smaller 
changes. When assessing copy number changes 
in unknown samples, it is important to use thresh-
olds with deﬁ  ned levels of conﬁ  dence. Since the 
median and mean Stouffer Z values were highly 
similar (Fig. 3D), in subsequent analyses we 
chose to use the mean values, plus or minus 2 
S.D. as the threshold value to identify chromo-
somal deletions and ampliﬁ  cations. These thresh-
old values are highlighted in Figure 3D.
Validation of known deletions 
and ampliﬁ  cations
Applying the cutoffs listed above, the known 
deletion on chromosome 4 (4p16.3) from the 
NA04126 cell line, derived from an individual 
with Wolf-Hirschorn syndrome, was detected with 
a number of probesets falling below the 2 S.D. 
line (Fig. 4). Of these, 4 probesets (shown as blue 
dots in the inset image) map to the WHCR gene, 
known to cause Wolf-Hirschorn syndrome. In 
contrast, analyzing the breast cancer cell line SK-
BR-3, in which portions of chromosome 8 q are 
known to be ampliﬁ  ed, a number of probesets are 
shown to be highly ampliﬁ  ed, including those 
representing the c-myc oncogene (Fig. 5). c-Myc 
is commonly ampliﬁ  ed in breast cancers and is 
known to be amplified in SK-BR-3. These 
data demonstrate that known deletions and 
ampliﬁ  cations in cell lines can be accurately 
detected using ECNA.
Copy number changes in GIST
The next step was to apply this methodology on 
tumor samples. GIST is an ideal tumor model for 
testing the sensitivity of this system, since it has 
relatively few copy number changes, and these 
are well-documented using both low and high 
resolution approaches (29, 36). We therefore 
analyzed 5 GIST genomic DNA samples for a 
global assessment of segmental gains and losses. 
Figure 6 shows the genomic view of the ECNA 
data for 3 of these tumors. There are chromosomal 
regions identiﬁ  ed as clearly changed in all three 
GIST samples compared to the control sample 
(Fig. 6A). For example, in all tumors, the majority 
of probe sets in 1p are well below the 2X copy 
number line (0 on the y-axis.) The 1p-arm appears 
to fall at about a 1X copy number, indicating loss 
of 1p, while 1q appears to be gained in these 
samples.
The 2 samples (GIST#159,199) originating 
from the same patient from two subsequent recur-
rences, at 14-month intervals, showed very good 
concordance overall between the copy number 
changes (Figs. 6C and 6D, and Supplementary 
Table 2). Interestingly, GIST#199, the later recur-
rence, showed additional losses at 5q23-35 and 
8p12-23 as compared to GIST#159, suggesting the 
possibility of deletions of candidate tumor sup-
pressor genes involved in tumor progression.
The copy number changes detected by ECNA 
are listed in Supplementary Table 2. Brieﬂ  y, the 
majority of GIST tumors showed losses of 14q 
(4/5 samples), 22q (3/5 samples) and 1p (5/5 
samples). Furthermore, smaller regions of loss 
were consistently noted, such as 1p36 (seen in 4/5 
GIST samples), 13q34 (4/5 samples) and 21q22 
(seen in 3/5 GISTs). The two GIST samples har-
boring mutations in PDGFRA exon 18 did not 
show distinct ﬁ  ndings compared to the 3 samples 
harboring mutations in exon 11 of the KIT gene. 
GIST#171 showed the lowest number of altera-
tions, while GIST#204 had the most copy number 
changes, more similar to the samples with KIT 
mutations. A summary of our ﬁ  ndings in com-
parison with other copy number analysis methods, 
such as CGH (1) and BAC-array CGH, for which 
results have been previously reported in GIST, is 
shown in Table 1.
To further validate our assay, we performed a 
comparison with another copy number technique 
with similarly high resolution. Figure 7 shows 
the concordance of our results on chromosome 1, 
with copy number analysis performed on the 
GeneChip Human Mapping100K arrays. Results 
are similar between the two methods; both reveal 
deletions and gains on chromosome 1p and 1q, 
respectively (Figs. 7A and B). The U133 Plus 2.0 
arrays are gene-centric, whereas the SNP arrays 
span coding as well as non-coding regions of the 
genome. This complementarity of coverage is 
evident in the distribution of probesets or SNPs 
in the respective arrays. The SNP arrays 
additionally provide allele-speciﬁ  c information, 
as illustrated by the loss of heterozygosity (LOH) 
results in Figure 7C.
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Figure 4. Detection of a known chromosome 4 deletion in a cell line derived from a Wolf-Hirschhorn patient. 211 probesets located 
at the p-arm are below the line at −7.7 and hence are called as deleted. 4 of these probesets (1556651_at, 1557300_s_at, 203112_s_at 
and 34225_at) map to the Wolf-Hirschhorn syndrome gene, and are shown in bold.
Figure 5. Detection of known chromosome 8 ampliﬁ  cations in the SK-BR-3 breast cancer cell line. The probeset corresponding to 
the c-MYC oncogene at chromosome 8q24 is located within the ampliﬁ  ed region and is indicated by the arrow.






Figure 6. A global view of copy number changes in GIST samples. Each chromosome is individually colored. The samples displayed here 
are Normal (A), GIST 198 (B), GIST 159 (C), and GIST 199 (D). The arrows indicate speciﬁ  c regions highlighted in the paper.The sample in 
D was obtained from the same patient as the sample in C but at a later time point (14 months), and shows additional losses at 5p and 8q.
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Comparison of copy number changes 
with expression data and validation 
using FISH
One-way ANOVA identiﬁ  ed probesets that were 
signiﬁ  cantly over- or under- expressed in GIST 
samples compared to leiomyosarcoma tumor 
samples. Some regions were identiﬁ  ed that showed 
both copy number change and a corresponding 
difference in expression as indicated by a signiﬁ  -
cant p-value. Some of these low p-value probesets 
were mapped back to the chromosomes and 
regions were selected that showed both copy 
number change as well as signiﬁ  cant difference in 
expression. Of these, two genes, PRKAR2B on 
chromosome 7 and PEX11B on chromosome 1 
showed gains of approximately 5-fold by their 
respective Stouffer Z scores, and expression levels 
that were signiﬁ  cantly higher in GIST compared 
to leiomyosarcomas. FISH analysis showed 
increased copies of PRKAR2B in the majority of 
the cells of GIST 198, 4–5 signals/nucleus 




Figure 7. Comparison of copy number results on chromosome 1 obtained with ECNA and Mapping 100K SNP arrays. Individual 
probesets or SNPs are represented by a vertical line mapped to chromosomal location. (top is +; bottom is −) Blank areas contain no probe-
sets or SNPs. A. ECNA copy number results. The probesets are colored according to Stouffer Z distribution from −10 to 10. B. 100K SNP 
array copy number results. The SNPs are colored according to copy number estimation from 1 to 3 obtained using the CNAT algorithm 
as described in Materials and Methods. C. LOH results from 100K SNP array.
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159, 2–3 signals/nucleus. However the reference 
centromeric chromosome 7 probe also showed 
increased copy number in all 3 GIST cases tested, 
with the PRKAR2B to chromosome 7 centromere 
ratio close to 1 (range 0.8–1.2). This result corre-
lates with the whole chromosome 7 gains observed 
in ECNA (Table 1). Similar ﬁ  ndings were found 
with PEX11B on 1q21.1, with extra copies of both 
PEX11B and chromosome 1, with a ratio close to 
1. One tumor (GIST199) showed 3–4 PEX11B 
signals/nucleus (Fig. 8B) and the other (GIST159) 
2–3 copies.
Discussion
In this study we designed a method to estimate 
chromosomal copy number by hybridizing genomic 
DNA to Human Genome U133 Plus 2.0 arrays, 
typically used to study levels of RNA expression. 
An important advantage of our novel assay is that 
it requires only a very limited amount of DNA, i.e. 
as little as 5 ng starting material. Additionally, 
many of the advantages of an established array 
platform such as whole genome representation, 
probe set annotations and algorithms to estimate 
probe set signals were available to us by using this 
expression array approach.
We developed this method by taking samples 
with known differences in X-chromosome copy 
number. We chose a sliding window approach to 
generate Stouffer Z scores that were used to esti-
mate copy number changes. The approach was then 
applied to and conﬁ  rmed on cell lines with known 
chromosomal abnormalities. Finally, we used this 
approach to assess copy number changes in gas-
trointestinal stromal tumor (GIST) samples. GISTs 
are known to have copy number aberrations, some 
of which have been identified by other tech-
niques.
In a recent study, Auer et al. (37) used a similar 
gene resolution analysis of copy number variation, 
the Affymetrix U133 Plus 2.0 arrays. Similarly, the 
authors conclude that this approach provides more 
reproducible results than custom-made BAC CGH 
arrays, that can be compared among different 
laboratories and can be combined with gene 
expression data using the same platform. Their 
results show a good concordance between the copy 
number changes detected by a 19k BAC high den-
sity microarray platform and the Affy expression 
arrays. Comparable with our approach, the authors 
choose various cell lines with known ampliﬁ  ca-
tions/deletions, such as neuroblastoma cell lines, 
to validate the variations in gene copy number. 
However they do not extend the use of this appli-
cation to routine clinical tumor samples.
The most common ﬁ  ndings, which have been 
reported by both conventional and BAC-array 
CGH, include losses of part or all chromosome 14, 
loss of chromosome 22, and loss of 1p (26, 29) 
(Table 1). Our method conﬁ  rmed these results, 
showing a high incidence of 14q, 22q and 1p losses. 
Furthermore, we provide evidence that increased 
resolution in the current platform facilitated the 
identiﬁ  cation of small alterations that were missed 
by a lower resolution BAC-array CGH platform. 
A
B
Figure 8. Conﬁ  rmation of novel gains on chromosomes 7q22 and 
1q21.2 using ﬂ  uorescence in situ hybridization (FISH): A. FISH 
for PRKAR2B on a touch preparation from GIST198. The majority of 
cells have 4 to 5 pairs of PRKAR2B (Red)/7 centromere (Green) 
signals. B. FISH for PEX11B on a parafﬁ  n section from GIST 199. The 
image is a compressed stack of 10 z-section images taken at 0.5 
micron intervals, allowing display of all signals present through the 
depth of the tissue section. The majority of cells have 3–4 copies of 
PEX11B (red), as well as at least 3 copies of chromosome 1 centro-
meric probe (green).
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Three areas of interest were pinpointed by this 
method including losses of 1p36, 13q34 and 21q22, 
the ﬁ  rst two previously highlighted by BAC array 
CGH, while the third locus being a novel ﬁ  nding. 
In addition, novel gains of PEX11 on 1q21 and 
PRKAR2B on 7q22 were conﬁ  rmed in this study 
via FISH and this chromosomal region was shown 
to have signiﬁ  cant difference in expression patterns 
when compared to a control sample.
Several copy number analysis methods are now 
available. The amount of DNA needed varies 
among the different methods, from as little as 5 ng 
as used in this study, to 400 ng (8) or 2 µg (7). 
ECNA uses whole genomic DNA without com-
plexity reduction followed by ampliﬁ  cation with 
φ29 DNA polymerase, in contrast to the WGSA 
method used on SNP arrays (8, 10, 31). We 
analyzed the same GIST samples with the SNP 
array method. Despite the fact that the assay and 
array designs are distinct, the results obtained are 
highly similar (Fig. 7). While the SNP arrays have 
very dense genomic coverage, the HG U133 Plus 
2.0 arrays are gene-centric, and so may have rep-
resentation in regions where SNP coverage is 
limited or absent. Thus, in addition to showing 
good concordance, these methods are complemen-
tary. Most copy number analysis methods described 
thus far generate a list of genomic regions undergo-
ing copy number alterations, without further details 
on their impact on gene expression. ECNA prom-
ises to link the areas of loss or gain with informa-
tion related to the expression level of their 
corresponding probe sets, as RNA from the same 
sample can be used to analyze levels of RNA 
expression on the same platform.
Many of the advantages of an established array 
platform such as whole genome representation, 
probe set annotations and algorithms to estimate 
probe set signals were available to us by using this 
expression array approach. A clear advantage to 
this approach is that copy number alterations may 
be studied in other species, such as mouse, rat, and 
other model organisms for which expression arrays 
are available, and for which SNPs have not yet 
been mapped. This assay has been successfully 
used by other researchers to detect copy number 
changes on HG U133 Plus 2.0 arrays (38). Addi-
tionally, experimental evidence has shown that this 
assay may be used on Affymetrix tiling arrays (K. 
Wu, unpublished data) to assess copy number 
changes. We also believe that this approach will 
prove valuable in studying copy number aberrations 
in clinical samples because of the availability of 
relatively small amounts of starting material.
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Supplementary Material
Data normalization: A two-step data normalization procedure was performed, to ensure that data from 
different experiments are comparable on the same scale. The ﬁ  rst step is a linear global normalization 
of each experiment individually through Affymetrix GCOS software. We chose a percent present call 
rate of 67% as a cut-off value to decide if a particular experiment should be used for downstream DNA 
copy number analysis. Of 79 U133 Plus 2.0 arrays that were hybridized for DNA copy number estima-
tion, 69 passed the 67% cutoff. These 69 linearly normalized experiments were carried on to the second 
normalization step. A quantile normalization procedure was applied to all 69 samples together using 
Partek software. The second step quantile normalization makes each experiment in the set have the 
same distribution, while maintaining the relative rank of individual probe set within each experiment.
Data ﬁ  ltering for “non-responsive” and cross-hybridizing probe sets: AFFX bacterial spike-in 
control probe sets, not used in the hybridizations in this study, were used to ﬁ  lter out “non-responsive” 
probe sets. The background signal distribution of the AFFX bacterial control probe sets was examined 
and the signal mean + one standard deviation was used as cutoff value to ﬁ  lter the average signal values 
in 20 normal human blood DNA samples. Probe sets in the normal blood DNA sample with average 
signal value below this cutoff in these 20 samples were excluded from all samples, and therefore from 
downstream copy number estimations. Cross-hybridizing probes were removed by ﬁ  ltering out all probe 
sets with designation of “_x_”, as well as “AFFX-hum_alu_at”. After ﬁ  ltering, 44688 probe sets (of a 
total 54675 probesets on the array) remained for downstream data analysis.
Probe set mapping to chromosome locations: Each probe set was mapped to its corresponding chro-
mosome location based on Affymetrix NetAFFX™ annotation (HG build 35). The mapped ﬁ  le was 
subsequently sorted by chromosome then by chromosome location. We used the middle point of the 
probe set selection region (PSR) as each probe set’s chromosomal coordinate.
Reference set selection: From the 69 quantile-normalized experiments, we partitioned the data into 
reference set and test set. Our reference set consists of 37 DNA samples which passed the QC param-
eter, and are representative of all sample types used in the study. The composition of the reference data 
set is shown in Table 1 (Supplement). We computed the normal distribution parameters for each probe 
set using a trimmed sample list for each probe set from the reference set. The top 10% and bottom 10% 
signal values in the training set were omitted, the remaining data values are used for computing refer-
ence set parameters.
Z-score computation: In order to estimate copy number, we ﬁ  rst consider each probe set as a single 
data point. To estimate the single point copy number, we used Z-score, derived from the standard nor-
mal distribution of the probe set signal. The Z scores are mapped to chromosomal locations based on 
Affymetrix NetAffx U133 Plus 2.0 array annotation (Human Genome Build 35). All data points are 
sorted ﬁ  rst by chromosome, then by chromosomal coordinates. To estimate the copy number of a region 
on a chromosome, we used the neighboring probe sets in a sliding window approach. We combined 
data points within a window using the meta-analytic technique Stouffer Z to obtain a signiﬁ  cant window 
(Sutton et al. 2000). We used a sliding window size of 500,000 bp in all Stouffer Z computations in this 
paper.
Sutton, A., K. Abrams, D. Jones, T. Sheldon, and F. Song. 2000. Methods for Meta-Analysis in 
Medical Research. John Wiley and Sons, Ltd.
Cancer Informatics 2008:6 74
Antonescu et al
Table S1. Experimental samples are listed by Experiment name, sample type, number of X chromosomes, 
gender, percent Present calls, and representation in the Reference set. All replicates (indicated by a, b or c) were 
at the sample preparation level, except for the Normal Blood DNA samples which were at the array hybridization 
level.
Expt Name Sample_type Gender ChrXCopy % Present Reference
1Xa Cell_line M 1 88.4 Y
1Xb Cell_line M 1 83.4 N
1Xc1 Cell_line M 1 76.9 N
1Xc2 Cell_line M 1 85.6 N
2Xa Cell_line F 2 82.2 Y
2Xb Cell_line F 2 86.8 Y
2Xc Cell_line F 2 88 Y
3Xa Cell_line F 3 89.2 Y
3Xb1 Cell_line F 3 80.8 Y
3Xb2 Cell_line F 3 88 N
3Xc1 Cell_line F 3 78.8 N
3Xc2 Cell_line F 3 87.5 N
4Xa Cell_line F 4 92.6 Y
4Xb Cell_line F 4 93.1 Y
4Xc Cell_line F 4 90.6 N
5Xa1 Cell_line F 5 76.9 Y
5Xa2 Cell_line F 5 84.7 Y
5Xb Cell_line F 5 88 N
5Xc Cell_line F 5 87.6 N
DelChr13a Cell_line F 2 86.2 Y
DelChr13b Cell_line F 2 85.3 Y
DelChr13c Cell_line F 2 87.8 Y
DelChr4a Cell_line F 2 67.2 Y
DelChr4a Cell_line M 1 86.8 N
DelChr4b Cell_line M 1 87.2 N
DelChr8a Cell_line M 1 70.2 N
DelChr8a Cell_line M 1 85.1 N
DelChr8b Cell_line M 1 83.5 N
DelChrXb Cell_line M 1 67.2 N
DelChrX_A Cell_line F 2 85.3 Y
DelChrX_B Cell_line F 2 88.1 Y
GIST159a GIST M 1 79.3 N
GIST159b GIST M 1 75 N
GIST171a GIST M 1 83.2 N
GIST171b GIST M 1 80.2 N
GIST198a GIST M 1 81.2 N
GIST198b GIST M 1 80.4 N
GIST199a GIST M 1 77.7 N
GIST199b GIST M 1 82.7 N
GIST204a GIST F 2 86.2 N
GIST204b GIST F 2 86.6 N
SKBR3a Cell_line F 2 94.5 N
SKBR3b Cell_line F 2 94.3 Y
Sample01A Normal_blood_DNA F 2 87.6 Y
(Continued)
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Table S1. (Continued)
Expt Name Sample_type Gender ChrXCopy % Present Reference
Sample01B Normal_blood_DNA F 2 80.4 Y
Sample01C Normal_blood_DNA F 2 78.6 Y
Sample02a Normal_blood_DNA F 2 80 Y
Sample02b Normal_blood_DNA F 2 74.8 Y
Sample02C Normal_blood_DNA F 2 83.9 Y
Sample03b Normal_blood_DNA F 2 77.8 Y
Sample04a Normal_blood_DNA F 2 73.7 Y
Sample04b Normal_blood_DNA F 2 78.2 Y
Sample04b Normal_blood_DNA F 2 81.9 Y
Sample05A Normal_blood_DNA M 1 85 Y
Sample05B Normal_blood_DNA M 1 81.8 N
Sample05C Normal_blood_DNA M 1 82.4 N
Sample06B Normal_blood_DNA M 1 78.8 Y
Sample07A Normal_blood_DNA M 1 86.4 N
Sample07B Normal_blood_DNA M 1 86 Y
Sample07C Normal_blood_DNA M 1 87.7 N
Sample08A Normal_blood_DNA F 2 84.6 Y
Sample08B Normal_blood_DNA F 2 88.8 Y
Sample08C Normal_blood_DNA F 2 84.8 Y
Sample09A Normal_blood_DNA M 1 86.2 Y
Sample09B Normal_blood_DNA M 1 88.2 Y
Sample09C Normal_blood_DNA M 1 89 N
Sample10A Normal_blood_DNA M 1 85.8 Y
Sample10B Normal_blood_DNA M 1 87.5 N
Sample10C Normal_blood_DNA M 1 79.4 Y
Table S2. 
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